Suspension of trading
Intra-Cellular Therapies, Inc. Share Price
Equities
ITCI
US46116X1019
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.87 USD | -0.04% |
|
-.--% | - |
| 15/25/15 | J&J Boosts Outlook Despite Incoming Tariff Costs -- Update | DJ |
| 15/25/15 | J&J Increases Outlook After Beating 1Q Expectations | DJ |
| Capitalization | 1.4TCr 1.18TCr 1.08TCr 1.03TCr 1.91TCr 1,27200Cr 1.97TCr 12TCr 4.98TCr 61TCr 5.26TCr 5.15TCr 2,15000Cr | P/E ratio 2023 |
-49.2x | P/E ratio 2024 | -115x |
|---|---|---|---|---|---|
| Enterprise value | 1.3TCr 1.1TCr 1.01TCr 955.54Cr 1.77TCr 1,18300Cr 1.83TCr 12TCr 4.63TCr 57TCr 4.89TCr 4.79TCr 1,99900Cr | EV / Sales 2023 |
13.8x | EV / Sales 2024 | 11.6x |
| Free-Float |
96.14% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -0.04% |
| 1 year | 127.72 |  | 131.98 |
| 3 years | 42.01 | | 131.98 |
| 5 years | 28.4 | | 131.98 |
| 10 years | 6.75 | | 131.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 73 | 29/08/2013 |
Juan Sanchez
IRC | Investor Relations Contact | - | - |
Michael Halstead
PSD | President | 53 | 19/03/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.04% | -.--% | +3.38% | +170.95% | 1.4TCr | |
| +3.19% | +0.50% | +17.06% | +2.82% | 7.75TCr | |
| -0.38% | -0.94% | +39.39% | +233.92% | 5.99TCr | |
| -6.33% | -15.34% | -40.13% | -49.70% | 5.84TCr | |
| +0.12% | +71.20% | +71.20% | +71.20% | 5.44TCr | |
| +1.17% | +3.10% | +37.17% | -33.22% | 2.77TCr | |
| -0.89% | +11.20% | +150.28% | +105.67% | 1.99TCr | |
| -1.21% | -3.66% | +49.01% | +24.70% | 1.96TCr | |
| -3.54% | -5.28% | +30.97% | -76.07% | 1.64TCr | |
| +2.10% | +13.90% | +27.56% | +67.02% | 1.55TCr | |
| Average | -0.56% | +1.90% | +38.59% | +51.73% | 3.63TCr | |
| Weighted average by Cap. | -0.44% | +0.63% | +30.75% | +52.44% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 46Cr 39Cr 36Cr 34Cr 63Cr 4.21TCr 65Cr 413.07Cr 164.93Cr 2.03TCr 174.16Cr 170.58Cr 7.12TCr | 68Cr 57Cr 53Cr 50Cr 93Cr 6.18TCr 96Cr 605.63Cr 241.81Cr 2.97TCr 255.35Cr 250.1Cr 10TCr |
| Net income | -14Cr -12Cr -11Cr -10Cr -19Cr -1.27TCr -20Cr -124.24Cr -50Cr -609.45Cr -52Cr -51Cr -2.14TCr | -7.47Cr -6.29Cr -5.76Cr -5.47Cr -10Cr -677.71Cr -10Cr -66Cr -27Cr -325.84Cr -28Cr -27Cr -1.14TCr |
| Net Debt | -48Cr -41Cr -37Cr -35Cr -65Cr -4.37TCr -68Cr -427.86Cr -170.83Cr -2.1TCr -180.4Cr -176.69Cr -7.37TCr | -98Cr -83Cr -76Cr -72Cr -133.73Cr -8.93TCr -138.25Cr -875.37Cr -349.51Cr -4.29TCr -369.07Cr -361.48Cr -15TCr |
Employees
860
Sector
Pharmaceuticals
- Stock Market
- Equities
- ITCI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition